Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 0.43 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.43 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL417945 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL2335688 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL5395427 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL5388585 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1707214 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2340421 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5473748 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8449813 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Iodide SCHEMBL5386794 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7142072 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357568-B2 | Aerosol formulation for COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-07-15 | — | — | US | claimed |
| EP-1755590-B1 | COMBINATION OF GLYCOPYRROLATE AND A BETA2 ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| US-20070185067-A1 | Ciclesonide and glycopyrronium combination | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20070167496-A1 | Roflumilast and glycopyrronium combination | ATTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | claimed |
| EP-1720577-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | Altana Pharma AG (DE) | 2006-11-15 | — | — | EP | claimed |
| WO-2005082413-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | ALTANA PHARMA AG (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20250262151-A1 | AEROSOL FORMULATION FOR COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-21 | — | — | US | disclosed |
| US-20250082588-A1 | PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-13 | — | — | US | disclosed |
| EP-3500241-B1 | COMBINATION THERAPY FOR COPD | CHIESI FARM SPA (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-2515855-B3 | Combination therapy for COPD | CHIESI FARM SPA (IT) | 2023-05-03 | — | — | EP | disclosed |
| EP-3574895-B1 | PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND | CHIESI FARM SPA (IT) | 2023-03-22 | — | — | EP | disclosed |
| EP-3405173-B1 | PREPARATION OF MICRONIZED PARTICLES OF AN ANTIMUSCARINIC COMPOUND BY HYDRODYNAMIC CAVITATION | CHIESI FARM SPA (IT) | 2022-12-07 | — | — | EP | disclosed |
| US-11389401-B2 | Combination therapy for COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-07-19 | — | — | US | disclosed |
| US-20160279066-A1 | PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-29 | — | — | US | disclosed |
| US-9393202-B2 | Particle size reduction of an antimuscarinic compound | CHIESI FARMACEUTICI S.P.A (IT) | 2016-07-19 | — | — | US | disclosed |
| US-20150328144-A1 | COMBINATION THERAPY FOR COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-19 | — | — | US | disclosed |
| US-20150182459-A1 | STABLE PRESSURISED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-07-02 | — | — | US | disclosed |
| US-20150182450-A1 | STABLE PRESSURISED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-07-02 | — | — | US | disclosed |
| US-20140322142-A1 | PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20110150782-A1 | COMBINATION THERAPY FOR COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185067-A1 | Ciclesonide and glycopyrronium combination | NR3C2, NR3C1, NR5A1 | CHRM3 74/4885CHRM2 412/4885CHRM4 302/4885 |
| US-20070167496-A1 | Roflumilast and glycopyrronium combination | ADAMTS5, TPO, ADAMTS4 | CHRM3 18/4885CHRM2 85/4885CHRM4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.